Literature DB >> 16194844

In vitro human osteoblast and extracellular matrix changes after transforming growth factor beta 1 treatment.

G Stabellini1, M Vertemati, P Locci, M Calvitti, E Minola, C Calastrini, A Pellati, F Carinci, L Marinucci, C Lilli, T Baroni.   

Abstract

AIMS: Normal bone tissue is characterised by a balancing of osteoblast and osteoclast activity. The activity and differentiation of these cells are regulated by vitamins, hormones and cytokines. The action of these factors on bone tissue cells depends on the composition and mineralisation of extracellular bone matrix. In particular, transforming growth factor beta 1 (TGFbeta1) acts on collagen fibres, glycosaminoglycan secretion and on the enzymes correlated to the turnover of glycosaminoglycans. The normal functions of bone tissue also depend on its mineralisation, which is highly altered in the process of uraemia.
METHODS: In this study, we analysed in vitro the effect of transforming growth factor beta on osteoblast proliferation, collagen synthesis and glycosaminoglycan secretion with 3H-thymidine, 3H-proline or 3H-glucosamine incorporation, and on enzymes, such as beta-N-acetyl-D-glucosaminidase and beta-glucuronidase, involved in extracellular matrix turnover. Moreover, phosphatase alkaline activity and osteocalcin related to mineralisation of extracellular matrix were determined.
RESULTS: Our data show that TGFbeta1 significantly decreases 3H-thymidine and 3H-proline incorporation and increases (p < or = 0.01) extracellular sulphated glycosaminoglycan synthesis. It also increases osteocalcin levels, phosphatase alkaline, beta-N-acetyl-D-glucosaminidase and beta-glucoronidase activities.
CONCLUSION: TGFbeta1 changes the synthesis of extracellular matrix components by osteoblasts. These variations favour the action of cytokine and osteoclasts. Since the TGFbeta1 accumulates in bone tissue and increases during uraemia, with due limitations this action leads to an imbalance between synthesis and degradation and could explain bone alterations in uraemic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16194844     DOI: 10.1080/00313020500254487

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

Review 1.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

2.  Heterotopic ossification in a patient with diffuse idiopathic skeletal hyperostosis: Input from histological findings.

Authors:  Caterina Licini; Luca Farinelli; Giorgia Cerqueni; Andrell Hosein; Saverio Marchi; Antonio Gigante; Monica Mattioli-Belmonte
Journal:  Eur J Histochem       Date:  2020-12-03       Impact factor: 3.188

3.  In Vitro Effects of PDGF Isoforms (AA, BB, AB and CC) on Migration and Proliferation of SaOS-2 Osteoblasts and on Migration of Human Osteoblasts.

Authors:  Alessandra Colciago; Fabio Celotti; Lavinia Casati; Rinaldo Giancola; Stefano M Castano; Guido Antonini; Maria Cristina Sacchi; Paola Negri-Cesi
Journal:  Int J Biomed Sci       Date:  2009-12

4.  Glycosaminoglycan and growth factor mediated murine calvarial cell proliferation.

Authors:  Kerry J Manton; Larisa M Haupt; Kumeri Vengadasalam; Victor Nurcombe; Simon M Cool
Journal:  J Mol Histol       Date:  2007-07-25       Impact factor: 3.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.